Evidence map›Paper›PMID 30935775›Full record

ArticleClinical colorectal cancer2019

Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Alissa Greenbaum, David R Martin, Thèrése Bocklage, Ji-Hyun Lee, Scott A Ness, Ashwani Rajput

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical colorectal cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alissa GreenbaumDivision of Surgical Oncology, Department of Surgery, University of New Mexico, Albuquerque, NM.
David R MartinDepartment of Pathology, University of New Mexico, Albuquerque, NM.
Thèrése BocklageDepartment of Pathology and Laboratory Medicine, University of Kentucky Albert B. Chandler Hospital, Lexington, KY.
Ji-Hyun LeeDepartment of Biostatistics, College of Public Health and Health Professions College of Medicine, University of Florida, Gainesville, FL.
Scott A NessDivision of Molecular Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM.
Ashwani RajputDivision of Surgical Oncology, Department of Surgery, University of New Mexico, Albuquerque, NM; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM. Electronic address: arajput@salud.unm.edu.

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Mutations and Target Genes in Adenoid Cystic CarcinomaR01DE023222 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Viswanathan Palanisamy · 2012 to 2026
$5.6M
Alternative RNA splicing and protein products in leukemia outcome (PQ11)R01CA170250 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI NESS, SCOTT A. · 2012 to 2015
$2.3M
NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA170250NIDCR NIH HHS R01 DE023222
6 · The paper itself

Abstract

backgroundNeoadjuvant chemoradiotherapy (nCRT) is the standard of care for locally advanced adenocarcinoma of the rectum, but it is currently unknown which patients have disease that will respond. This study tested the correlation between response to nCRT and intratumoral heterogeneity using next-generation sequencing assays. PATIENTS AND

methodsDNA was extracted from formalin-fixed, paraffin-embedded biopsy samples from a cohort of patients with locally advanced rectal adenocarcinoma (T3/4 or N1/2 disease) who received nCRT. High read-depth sequencing of > 400 cancer-relevant genes was performed. Tumor mutations and variant allele frequencies were used to calculate mutant-allele tumor heterogeneity (MATH) scores as measures of intratumoral heterogeneity. Response to nCRT was pathologically scored after surgical resection.

resultsBiopsy samples from 21 patient tumors were analyzed. Eight patients had disease noted to have complete response, 2 moderate, 4 minimal, and 7 poor. Higher MATH scores correlated with poorer response to treatment, demonstrating significantly increased tumor heterogeneity compared to complete response (P = .039).

conclusionThe application of MATH scores as a measure of tumor heterogeneity may provide a useful biomarker for treatment response in locally advanced rectal cancer.

Indexed as

AdenocarcinomaAllelesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsyChemoradiotherapy, AdjuvantDNA Mutational AnalysisFemaleGenetic HeterogeneityHigh-Throughput Nucleotide SequencingHumansMaleMutationNeoadjuvant TherapyNeoplasm StagingPatient SelectionBiomarkers, TumorBioinformaticsColorectal cancerPersonalized medicineTargeted sequencingTranslational research

Identifiers

PMID30935775
PMCPMC6556409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.